Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Disease-responsive Synthetic Cell Therapy

Project description

Programmable synthetic cells for precision drug delivery

Precision medicine is aimed at delivering the right treatment at precise locations and times. Existing strategies involving engineered cell therapies and synthetic drug delivery systems carry significant limitations, including immune rejection, poor targeting and uncontrolled drug release. Synthetic cells offer a promising alternative, combining the adaptability of living therapies with the controllability of synthetic systems. With the support of the Marie Skłodowska-Curie Actions programme, the Reactive SynCell project aims to develop programmable synthetic cells that sense hallmark features of diseased tissue such as low oxygen and acidity. The idea is to integrate synthetic biology, microfluidics and biomembrane engineering so that these cells respond by producing and releasing therapeutic proteins on demand. Potential applications include cancer and neurodegeneration.

Objective

This project aims to develop programmable, disease-responsive synthetic cells capable of sensing and adapting to pathological microenvironments—specifically hypoxia and acidity—by synthesizing and releasing therapeutic proteins on demand. Synthetic Cell Therapy, a novel class of precision medicine, will combine the adaptability of engineered living cell therapies with the precision and controllability of synthetic drug delivery systems. By leveraging the safety, modularity, and programmability of bottom-up synthetic biology, the proposed work addresses key limitations of current therapeutics, including immune rejection and uncontrolled behavior (engineered cell therapy), poor targeting and premature drug release (synthetic drug delivery system).
Two complementary strategies will be explored: (1) gene circuit–mediated therapeutic synthesis and release, and (2) physicochemical multi-stage drug release. WP1 will develop stimuli-responsive gene circuits for in situ transcription–translation of therapeutic proteins and pore-formers within microfluidic-generated synthetic cells, enabling real-time, stimuli-triggered therapeutic action. WP2 will engineer multi-compartmental synthetic cells with membrane lipids responsive to hypoxia and acidity, enabling graded, multi-stage release based on disease severity. Together, these approaches offer lifelike adaptive therapeutic behavior with spatial, temporal, and dosage control.
This interdisciplinary proposal integrates synthetic biology, microfluidics, biomembrane engineering, and pharmaceutical sciences, aligning with MSCA priorities in excellence, interdisciplinary and frontier research. The project addresses unmet medical needs in cancer and neurodegeneration and advances next-generation, safe, and intelligent precision medicine platforms, contributing to the Horizon Europe goals of fostering innovation, strengthening Europe's research competitiveness, and improving healthcare outcomes.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Net EU contribution
€ 260 347,92
Address
SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
SW7 2AZ London
United Kingdom
Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)